Factors Influencing Adherence to Mesalamine in Patients with Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis

Moss, Alan C.; Beusterien, K.; Ahmed, Awais; Cheifetz, Adam S.; Devlen, Jennifer; Yen, L

doi:10.14309/00000434-201110002-01177

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 26 , 76 – 78 A variety of barriers to adherence have been reported by patients, including lifestyle, risk of side effects, and financial factors. 79 , 80 A once-daily dose of mesalamine has been shown as effective as twice daily, with improved patient compliance in those with reduced pill burden. 81 However, a meta-analysis by Ford et al comparing once-daily dosing with mesalamine with conventional dosing schedules showed no significant benefit of once daily over multiple doses in risk of nonadherence (relative risk [RR], 0.87; 95% CI: 0.46–1.66).…”

Section: Focus On MMX ® Mesalaminementioning

confidence: 99%

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Nanda¹,

Moss²

2012

CPAA

Self Cite

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon that typically manifests as diarrhea, abdominal pain, and bloody stool. Complications, such as colorectal cancer and extraintestinal manifestations, may also develop. The goals of management are to induce and maintain clinical remission and to screen for complications of this disease. Mesalamine is a 5-aminosalicylic acid compound that is the first-line therapy to induce and maintain clinical remission in patients with mild-to-moderate UC. For patients who are refractory to mesalamine or have more severe disease, steroids, azathioprine/mercaptopurine, cyclosporine, or infliximab may be used, induce and/or maintain remission. The various formulations of mesalamine available are primarily differentiated by the methods of delivery of the active compound of the drug to the colon. Mesalamine with Multi-Matrix System® (MMX) technology (Cosmo SpA, Milan, Italy) is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC (Lialda® or Mezavant®, Shire Pharmaceuticals Inc, Wayne, PA). In clinical studies, MMX mesalamine (taken as a once-daily dose of 2.4 or 4.8 g) effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. The overall safety profile of MMX mesalamine is similar to other oral mesalamine formulations. The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy.

show abstract

Section: Focus On MMX ® Mesalaminementioning

confidence: 99%

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Nanda¹,

Moss²

2012

CPAA

Self Cite

View full text Add to dashboard Cite

show abstract

Current and emerging maintenance therapies for ulcerative colitis

OʼConnor

Moss

2014

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic idiopathic intestinal disease that requires life-long maintenance therapy to maintain clinical remission. This article reviews the current literature on maintenance treatments in UC. It examines the natural history of the condition and the proposed benefits of treatment. These include improving quality of life parameters, decreasing corticosteroid intake, the prevention of relapse, the prevention of colorectal cancer and the avoidance of colectomy. The immunosuppressive era appears to be reducing the need for elective colectomy in UC. The article explores the classes of drug currently used for maintenance of UC, reviews the literature around adherence issues, and summarizes emerging agents in this space.

show abstract

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

Ham

Moss²

2012

Expert Review of Clinical Pharmacology

121

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic disease of the GI tract that is characterized by mucosal inflammation in the colon. Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC. There are multiple formulations of mesalamine available, primarily differentiated by their means of delivering active mesalamine to the colon. Mesalamine has been demonstrated in randomized controlled trials to induce both clinical response and remission, and maintain clinical remission, in these patients. It has few serious adverse effects and is generally well tolerated by patients. The main areas of uncertainty with use of mesalamine in patients with UC center on the optimal dose for induction of response, how to maintain patient adherence and the role of mesalamine in cancer chemoprophylaxis. Generic forms of mesalamine have yet to be approved by regulatory bodies in the USA.

show abstract

Factors Influencing Adherence to Mesalamine in Patients with Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis

Cited by 3 publications

References 0 publications

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Current and emerging maintenance therapies for ulcerative colitis

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

Contact Info

Product

Resources

About

Factors Influencing Adherence to Mesalamine in Patients with Inflammatory Bowel Disease: A Patient-Reported Qualitative Analysis

Cited by 3 publications

References 0 publications

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX&reg; mesalamine

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX&reg; mesalamine

Current and emerging maintenance therapies for ulcerative colitis

Mesalamine in the treatment and maintenance of remission of ulcerative colitis

Contact Info

Product

Resources

About

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine